依达拉奉治疗急性脑梗死的临床效果观察

Clinical Observation of Edaravone in the Treatment of Acute Cerebral Infarction

目的观察依达拉奉治疗急性脑梗死临床疗效。方法选取2016年7月至2018年12月遂宁市中心医院收治的80例急性脑梗死患者,采用随机数字表法分为观察组和对照组,各40例。对照组给予常规治疗,观察组在常规治疗基础上加用依达拉奉。采用美国国立卫生研究院卒中量表(NIHSS)及日常生活能力指数(Barthel)对比治疗前后两组的临床治疗效果。结果治疗两周后,观察组患者NIHSS评分低于对照组;Barthel指数评分高于对照组;观察组患者临床治疗效果明显优于对照组,差异有统计学意义(P<0.05)。结论急性脑梗死加用依达拉奉注射液治疗可以有效改善患者神经功能缺损症状,改善其预后。

Objective To observe the clinical efficacy of edaravone in the treatment of acute cerebral infarction.Methods From July 2016 to December 2018,80 patients with acute cerebral infarction admitted to Suining Central Hospital were randomly divided into observation group and control group with 40 cases in each group.The control group was given routine treatment,and the observation group was given edaravone on the basis of routine treatment.NIHSS and Barthel were used to compare the clinical effects of the two groups before and after treatment.Results After 2 weeks of treatment,the NIHSS score of the observation group was lower than that of the control group;the Barthel index score was higher than the control group.The clinical treatment effect of the patients was significantly better than that of the control group,and the difference was statistically significant(P<0.05).Conclusion Acute cerebral infarction plus edaravone injection can effectively improve the symptoms of neurological deficit and improve the prognosis.